Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
Hoffmann-La Roche
Enriqueta Felip; Nasser Altorki; Caicun Zhou; Eric Vallières; Tibor Csoszi; Ihor O Vynnychenko; Oleksandr Goloborodko; Achim Rittmeyer; Martin Reck; Alex Martinez-Marti; Hirotsugu Kenmotsu; Yuh-Min Chen; Antonio Chella; Shunichi Sugawara; Chenqi Fu; Marcus Ballinger; Yu Deng; Minu K Srivastava; Elizabeth Bennett; Barbara J Gitlitz; Heather A Wakelee; IMpower010 Study Investigators